SciBase Holding AB (OSTO:SCIB) Risk Assessment


OSTO:SCIB SciBase Holding AB OSTO:SCIB
50 GF Score
Price kr32.60
GF Value kr21.73
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is SciBase Holding AB Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of SciBase Holding AB is: High Risk: High uncertainty with risk-return tradeoff.

SciBase Holding AB  (OSTO:SCIB) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

SciBase Holding AB Risk Assessment Related Terms

OSTO:SCIB vs ABT, SYK, MDT: Risk Assessment Comparison

For the Medical Devices subindustry, SciBase Holding AB's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciBase Holding AB Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SciBase Holding AB's Risk Assessment distribution charts can be found below:

* The bar in red indicates where SciBase Holding AB's Risk Assessment falls into.


OSTO:SCIB
50GF Score
SciBase Holding AB OSTO:SCIB
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?

Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued. The current stock price of kr32.60 is trading 50% above its estimated GF Value™ of kr21.73. GuruFocus considers SciBase Holding AB to be Significantly Overvalued.

Key valuation signals for OSTO:SCIB:

  • Risk Assessment:
  • GF Value™: kr21.73 vs. price of kr32.60 (50% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SciBase Holding AB Business Description

Address Landsvagen 39, Sundbyberg, Stockholm, SWE, 172 63
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
50GF Score

Get the complete analysis for OSTO:SCIB

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr32.60
Price
kr21.73
GF Value